Research / AI Drug Discovery

AI Drug Discovery

Machine learning finds new medicine targets and designs custom molecules — compressing a process that once took years into a timeline measured in months.

The Challenge

Traditional Drug Discovery Is Broken

Bringing a single new drug to market takes an average of 12–15 years and costs more than $2 billion — and nine out of ten candidates fail before reaching patients. The bottleneck is not scientific ambition but the speed at which biological hypotheses can be tested.

AI Drug Discovery addresses this directly: by running millions of virtual experiments simultaneously, our platforms explore molecular space orders of magnitude faster than any laboratory can, surfacing the candidates most likely to succeed before a single synthesis reaction is performed.

Speed

Lead Identification in Months

Our AI pipelines compress traditional 2–4 year lead identification programs to 3–6 months by screening billions of molecular configurations computationally.

Scale

Billions of Virtual Candidates

Generative models explore molecular space that no human chemist could navigate manually — including novel scaffolds and multi-target designs that emerge only at scale.

Precision

ADMET-Optimized Molecules

Every candidate is simultaneously scored for absorption, distribution, metabolism, excretion, and toxicity — reducing late-stage failures driven by poor pharmacokinetics.

Research Programs

Active Drug Discovery Programs

Target Atlas — Pan-Cancer AI Target Discovery

Multi-omics AI platform identifying novel druggable targets across 22 cancer types by integrating genomic, proteomic, and clinical outcome data from 50,000-patient cohorts.

Drug Discovery

MolGen — Generative Molecular Design Engine

Transformer-based generative chemistry model that designs novel small molecules optimized for binding affinity, selectivity, and synthetic accessibility in a single inference pass.

Drug Discovery

RepurposeAI — Drug Repurposing Discovery

Knowledge graph AI mining FDA-approved drug databases, clinical trial outcomes, and molecular interaction networks to identify repurposing candidates for rare and neglected diseases.

Drug Discovery

CombineX — Combination Therapy Optimizer

Reinforcement learning system that predicts synergistic drug combinations for treatment-resistant oncology and infectious disease applications, reducing combinatorial experimental burden by 95%.

Drug Discovery

SafetyNet — Predictive Toxicology Platform

Deep learning toxicity prediction trained on clinical adverse event databases and in vitro assay results, flagging safety liabilities before compounds enter animal studies.

Drug Discovery

← All Research Areas All Programs